Acute rhinosinusitis
Conditions
Interventions
Only as for the same antimicrobial
Same antimicrobial and Carbocisteine (1,500 mg/ day) 3 times/ day
Only as for the antimicrobial which I changed
Only as for the antimicrobial which I changed and Car
Sponsors
Wakayama-Okayama Otolaryngology Pharma
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patient with acute rhinosinusitis 2.Patient who are 20 years old or older at the time of giving informed consent 3.Patients who are classified as mild and do not show improvement in 5 days or classified as moderate or more in severity assessment in the clinical guideline for acute rhinosinusitis 4.Patients with the score 1 or more in the nasal findings in the scoring system for acute rhinosinusitis in 5 days after the administration of antibiotics 5.Patients giving written informed consent to this study
Exclusion criteria
Exclusion criteria: 1.Patients who cannot tolerate carbocisteine 2.Patients who received airway disease drugs (mucolytic agents) within 10 days to the start of this study 3.Patients who were scheduled to later receive airway disease drugs at the start of this study 4.Patients participating in other studies at the start of this study 5.Patients with history of severe hepatic diseases, renal diseases, cardiovascular diseases, or other cormobidities 6.Patients with a complication of malignant tumors 7.Women who are not pregnant or lactating, and not expecting future pregnancy 8.Patients who are judged inappropriate by physicians in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Change in scores of scoring system for assessing the clinical severity of acute rhinosinusitis To measure the change in scores within the group between day 10 to 14 (day 5 to 7) To measure the score (rate of change) between the groups between day 10 to 14 (day 5 to 7) 2.Change in total score of 8 items in daily report To measure the hange in scores within the group | — |
Countries
Japan
Outcome results
None listed